LS&HC Horizons 2023 - Flipbook - Page 66
66
11
United States
Market access planning in the aftermath of the IRA
67
U.S. life sciences procurement outlook for 2023
68
FDA’s cosmetics expansion
69
Removing barriers to research with Schedule I
controlled substances
70
State licensing requirements: what medical device
manufacturers need to know
71
Complex generics
72
Antitrust agencies expand potential antitrust theories
in merger reviews
73
